Annual CFI
$16.20 M
-$10.26 M-38.79%
31 December 2023
Summary:
Aileron Therapeutics annual cash flow from investing activities is currently $16.20 million, with the most recent change of -$10.26 million (-38.79%) on 31 December 2023. During the last 3 years, it has risen by +$9.79 million (+152.63%). ALRN annual CFI is now -38.79% below its all-time high of $26.46 million, reached on 31 December 2022.ALRN Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$0.00
$0.000.00%
30 September 2024
Summary:
Aileron Therapeutics quarterly cash flow from investing activities is currently $0.00, unchanged on 30 September 2024. Over the past year, it has dropped by -$542.00 thousand (-100.00%). ALRN quarterly CFI is now -100.00% below its all-time high of $12.58 million, reached on 30 June 2018.ALRN Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$96.00 K
-$542.00 K-121.52%
30 September 2024
Summary:
Aileron Therapeutics TTM cash flow from investing activities is currently -$96.00 thousand, with the most recent change of -$542.00 thousand (-121.52%) on 30 September 2024. Over the past year, it has dropped by -$21.15 million (-100.46%). ALRN TTM CFI is now -100.32% below its all-time high of $30.26 million, reached on 31 March 2019.ALRN TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALRN Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.8% | -100.0% | -100.5% |
| 3 y3 years | +152.6% | -100.0% | +99.8% |
| 5 y5 years | -34.4% | -100.0% | -113.2% |
ALRN Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -38.8% | +145.1% | -100.0% | +100.0% | -100.4% | +99.8% |
| 5 y | 5 years | -38.8% | +145.1% | -100.0% | +100.0% | -100.4% | +99.8% |
| alltime | all time | -38.8% | +141.6% | -100.0% | +100.0% | -100.3% | +99.8% |
Aileron Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(0.0%) | -$96.00 K(-121.5%) |
| June 2024 | - | $0.00(0.0%) | $446.00 K(-95.0%) |
| Mar 2024 | - | $0.00(-100.0%) | $8.95 M(-44.8%) |
| Dec 2023 | $16.20 M(-38.8%) | -$96.00 K(-117.7%) | $16.20 M(-23.1%) |
| Sept 2023 | - | $542.00 K(-93.6%) | $21.06 M(-14.7%) |
| June 2023 | - | $8.50 M(+17.2%) | $24.70 M(+11.9%) |
| Mar 2023 | - | $7.25 M(+52.2%) | $22.06 M(-16.6%) |
| Dec 2022 | $26.46 M(-173.7%) | $4.76 M(+13.9%) | $26.46 M(+10.5%) |
| Sept 2022 | - | $4.18 M(-28.7%) | $23.95 M(+0.4%) |
| June 2022 | - | $5.86 M(-49.7%) | $23.85 M(+80.8%) |
| Mar 2022 | - | $11.65 M(+417.5%) | $13.19 M(-136.7%) |
| Dec 2021 | -$35.92 M(-660.2%) | $2.25 M(-44.9%) | -$35.92 M(-6.8%) |
| Sept 2021 | - | $4.09 M(-185.2%) | -$38.52 M(-18.3%) |
| June 2021 | - | -$4.80 M(-87.2%) | -$47.14 M(+12.0%) |
| Mar 2021 | - | -$37.46 M(>+9900.0%) | -$42.11 M(-756.8%) |
| Dec 2020 | $6.41 M | -$357.00 K(-92.1%) | $6.41 M(-44.4%) |
| Sept 2020 | - | -$4.53 M(-1995.0%) | $11.53 M(-41.8%) |
| June 2020 | - | $239.00 K(-97.8%) | $19.80 M(+7205.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $11.06 M(+132.1%) | $271.00 K(-109.6%) |
| Dec 2019 | -$2.81 M(-111.4%) | $4.76 M(+27.5%) | -$2.81 M(-487.1%) |
| Sept 2019 | - | $3.74 M(-119.4%) | $727.00 K(-145.3%) |
| June 2019 | - | -$19.29 M(-341.9%) | -$1.61 M(-105.3%) |
| Mar 2019 | - | $7.97 M(-4.0%) | $30.26 M(+22.6%) |
| Dec 2018 | $24.69 M(-163.4%) | $8.30 M(+491.5%) | $24.69 M(+18.1%) |
| Sept 2018 | - | $1.40 M(-88.8%) | $20.90 M(-195.3%) |
| June 2018 | - | $12.58 M(+424.1%) | -$21.94 M(-24.9%) |
| Mar 2018 | - | $2.40 M(-46.9%) | -$29.21 M(-24.9%) |
| Dec 2017 | -$38.91 M(>+9900.0%) | $4.52 M(-110.9%) | -$38.91 M(-7.2%) |
| Sept 2017 | - | -$41.44 M(-880.5%) | -$41.95 M(-1141.6%) |
| June 2017 | - | $5.31 M(-172.7%) | $4.03 M(+31.4%) |
| Mar 2017 | - | -$7.30 M(-592.1%) | $3.06 M(<-9900.0%) |
| Dec 2016 | -$25.00 K(-100.2%) | $1.48 M(-67.3%) | -$25.00 K(-98.3%) |
| Sept 2016 | - | $4.54 M(+4.4%) | -$1.51 M(-75.0%) |
| June 2016 | - | $4.35 M(-141.8%) | -$6.05 M(-41.8%) |
| Mar 2016 | - | -$10.39 M | -$10.39 M |
| Dec 2015 | $10.63 M | - | - |
FAQ
- What is Aileron Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Aileron Therapeutics?
- What is Aileron Therapeutics annual CFI year-on-year change?
- What is Aileron Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Aileron Therapeutics?
- What is Aileron Therapeutics quarterly CFI year-on-year change?
- What is Aileron Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Aileron Therapeutics?
- What is Aileron Therapeutics TTM CFI year-on-year change?
What is Aileron Therapeutics annual cash flow from investing activities?
The current annual CFI of ALRN is $16.20 M
What is the all time high annual CFI for Aileron Therapeutics?
Aileron Therapeutics all-time high annual cash flow from investing activities is $26.46 M
What is Aileron Therapeutics annual CFI year-on-year change?
Over the past year, ALRN annual cash flow from investing activities has changed by -$10.26 M (-38.79%)
What is Aileron Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of ALRN is $0.00
What is the all time high quarterly CFI for Aileron Therapeutics?
Aileron Therapeutics all-time high quarterly cash flow from investing activities is $12.58 M
What is Aileron Therapeutics quarterly CFI year-on-year change?
Over the past year, ALRN quarterly cash flow from investing activities has changed by -$542.00 K (-100.00%)
What is Aileron Therapeutics TTM cash flow from investing activities?
The current TTM CFI of ALRN is -$96.00 K
What is the all time high TTM CFI for Aileron Therapeutics?
Aileron Therapeutics all-time high TTM cash flow from investing activities is $30.26 M
What is Aileron Therapeutics TTM CFI year-on-year change?
Over the past year, ALRN TTM cash flow from investing activities has changed by -$21.15 M (-100.46%)